Introduction {#s1}
============

Deep sternal wound infections (DSWI), namely mediastinitis and osteomyelitis, are a serious complication occurring in 1% to 5% of patients after cardiothoracic operations in individual studies.[@pone.0064741-Bovill1], [@pone.0064741-Fleck1] Intravenous antibiotics and several surgical techniques had been used in the past for their treatment; however, they have been associated with increased short- and long-term mortality.[@pone.0064741-Toumpoulis1] A new technique using topical negative pressure by controlled suction has been introduced in the treatment of wounds achieving wound closure through the formation of granulation tissue. This technique, most commonly applied by vacuum-assisted closure (VAC) wound therapy system, has gradually gained ground and replaced most of the conventional types of wound treatment due to the faster wound healing,[@pone.0064741-Armstrong1], [@pone.0064741-Joseph1], [@pone.0064741-Vuerstaek1] lower length of hospital stay[@pone.0064741-Catarino1], [@pone.0064741-Doss1], [@pone.0064741-Gabriel1] and the subsequent lower in-hospital cost.[@pone.0064741-Vuerstaek1], [@pone.0064741-Flack1].

Moreover, early studies showed that VAC therapy has the potential to reduce both in-hospital and long-term mortality.[@pone.0064741-Sjogren1], [@pone.0064741-Sjogren2] A meta-analysis published in 2011 showed that patients treated with VAC had shorter duration of hospitalization but no difference in mortality compared to those treated with a non-VAC therapy.[@pone.0064741-Damiani1] Since this publication several new studies became available that expanded our knowledge regarding the effectiveness of VAC application for the treatment of sternal wound infections. We aimed to systematically review and synthesize the available evidence with the methodology of meta-analysis in order to examine the impact of VAC therapy on mortality of patients with sternal wound infections.

Methods {#s2}
=======

Literature Search {#s2a}
-----------------

We performed a systematic search in PubMed and Scopus electronic databases in September 2012. The search term that was applied in PubMed was the following: ("negative pressure" OR vac OR "vacuum assisted") AND (wound) AND (infection). A more conservative search term was applied in Scopus database: (\"negative pressure\" OR vac OR \"vacuum assisted\") AND (sternal wound infection OR dswi OR mediastinitis OR osteomyelitis). In addition, the bibliographies of all relevant articles were searched in order to identify further potentially eligible studies. Articles written in a language other than English, German, French, Spanish, Italian or Greek were not evaluated. Only published studies were included; abstracts from conferences were excluded.

Study Selection {#s2b}
---------------

Articles reporting the comparative outcomes of patients with sternal wound infections treated with VAC versus a non-VAC therapy were considered eligible for the meta-analysis regardless of the study design, patient characteristics, type of surgery and additional used interventions, deep or superficial sternal wound infections. When a patient population was included in more than one published studies, only the study with the bigger total study population was included. Studies focusing primarily in sternal wounds without infections or other types of wounds were excluded.

Data Extraction {#s2c}
---------------

Data was extracted regarding the major characteristics of the included studies (first author, country, period of the study, study design), number of patients in each treatment arm, group establishment regarding the type of therapy selected, patient co-morbidity regarding the cardiothoracic operations conducted, and time of mortality assessment.

Definitions and Outcomes {#s2d}
------------------------

Sternal wound infections could comprise both deep and superficial infections developed after a cardiothoracic surgery. The definition of osteomyelitis, mediastinitis and superficial wound infections was based on the definitions provided by the selected individual studies.

The primary outcome of the review was in-hospital mortality. When in-hospital mortality was not provided by the authors of a study, 30-day or 90-day mortality was selected. Secondary outcomes comprised recurrence, as defined by the authors of the included studies, and hospital length of stay (LOS).

Statistical Analysis {#s2e}
--------------------

The non-randomized studies that were analyzed were considered to be heterogeneous by definition and therefore, the Mantel-Haenszel random effects model (REM) was applied. Pooled risk ratios (RR) and 95% confidence intervals (CI) were calculated regarding all outcomes. Statistical heterogeneity between studies was assessed by using the *χ* ^2^ test (p\<0.10 was defined to indicate the presence of heterogeneity) and the *I* ^2^ (for assessing the degree of heterogeneity). The meta-analysis was performed with Review Manager for Windows, version 5.1.

Results {#s3}
=======

The systematic search in both databases generated 938 articles (754 PubMed, 172 Scopus, 12 hand-searching). The selection process that was followed for the inclusion of the studies is depicted in [Figure 1](#pone-0064741-g001){ref-type="fig"}. Twenty-two studies were finally included in the review.[@pone.0064741-Doss1], [@pone.0064741-Sjogren1], [@pone.0064741-Assmann1], [@pone.0064741-Baillot1], [@pone.0064741-Berg1], [@pone.0064741-DeFeo1], [@pone.0064741-DeFeo2], [@pone.0064741-Deniz1], [@pone.0064741-Domkowski1], [@pone.0064741-Eyileten1], [@pone.0064741-Fleck2], [@pone.0064741-Fuchs1], [@pone.0064741-Immer1], [@pone.0064741-Kobayashi1], [@pone.0064741-Morisaki1], [@pone.0064741-Petzina1], [@pone.0064741-Risnes1], [@pone.0064741-RodriguezCetinaBiefer1], [@pone.0064741-Segers1], [@pone.0064741-Simek1], [@pone.0064741-Steingrimsson1], [@pone.0064741-Vos1] The characteristics of the included studies are presented in [Table 1](#pone-0064741-t001){ref-type="table"}. Twenty one studies reported on deep sternal wound infections (16 on mediastinitis,[@pone.0064741-Sjogren1], [@pone.0064741-Assmann1], [@pone.0064741-Baillot1], [@pone.0064741-Berg1], [@pone.0064741-DeFeo1], [@pone.0064741-DeFeo2], [@pone.0064741-Deniz1], [@pone.0064741-Domkowski1], [@pone.0064741-Eyileten1], [@pone.0064741-Fuchs1], [@pone.0064741-Morisaki1], [@pone.0064741-Petzina1], [@pone.0064741-Risnes1], [@pone.0064741-Segers1], [@pone.0064741-Steingrimsson1], [@pone.0064741-Vos1] two on osteomyelitis[@pone.0064741-Doss1], [@pone.0064741-Kobayashi1] and 3 did not specify the type of infections[@pone.0064741-Immer1], [@pone.0064741-RodriguezCetinaBiefer1], [@pone.0064741-Simek1]). One study included both deep (69%) and superficial (31%) sternal wound infections.[@pone.0064741-Fleck2] All included studies were retrospective cohorts. Thirteen of the 22 studies provided data with regard to the VAC system that was applied and in all of them the KCI (Kinetic Concepts, Inc.) system was used.[@pone.0064741-Doss1], [@pone.0064741-Assmann1], [@pone.0064741-DeFeo1], [@pone.0064741-DeFeo2], [@pone.0064741-Deniz1], [@pone.0064741-Eyileten1], [@pone.0064741-Fleck2], [@pone.0064741-Fuchs1], [@pone.0064741-Immer1], [@pone.0064741-Risnes1], [@pone.0064741-Segers1], [@pone.0064741-Simek1], [@pone.0064741-Steingrimsson1] Data regarding funding was provided by 4 studies;[@pone.0064741-Sjogren1], [@pone.0064741-DeFeo2], [@pone.0064741-Fleck2], [@pone.0064741-Steingrimsson1] only one was industry funded.[@pone.0064741-Fleck2].

![Flow diagram of the systematic search and study selection process.](pone.0064741.g001){#pone-0064741-g001}
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###### Characteristics of the studies included in the meta-analysis**.**

![](pone.0064741.t001){#pone-0064741-t001-1}

  First authorYear                                         Study design; period, country                         Number of analyzed patients (VAC vs non-VAC)                                                                                Patient co-morbidity                                                                                                                    Group establishment                                       System of VAC used   Mortality assessed at                              Funded or non-funded study
  --------------------------------- --------------------------------------------------------------------------- ---------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- -------------------- ----------------------- ----------------------------------------------------------------------------------
  Deniz2012^19^                                      Retrospective cohort; 2000--2011, Turkey                                   90 (47 vs 43)                                      60% coronary artery bypass revascularization, isolated 32% valvular procedure, 8% valvular in combination with coronary bypass procedures                                                  2000--2003: non-VAC2003--2011: VAC                                   KCI system              90-day                                                  NR
  Fleck2012^22^                                      Retrospective cohort; 1995--2011, Austria                                 524 (326 vs 198)                                   Cardiac operations (VAC group: 62% aorto-coronary artery bypass, 39% VR, 17% congenital surgery or aortic surgery or heart transplantation)                                                 1995--2001: non-VAC2002--2011: VAC                                   KCI system           Undetermined                                            KCI, USA
  Risnes2012^28^                                     Retrospective cohort; 1997--2010, Norway                                   104 (64 vs 66)                                                                                                       CABG                                                                                                     1997--2002: non-VAC2002--2006: both non-VAC and VAC2006--2010: VAC                   KCI system              30-day                                                  NR
  Rodriguez Cetina Biefer2012^29^                    Retrospective cohort; 1999--2008,Portugal                                 159 (105 vs 54)                                     51% CABG, 18% isolated valve, 18% CABG/valve, 14% other procedures (thoracic aneurysms, aortic dissections, congenital repair procedures)                        According to the surgeon's discretion; VAC available for use at the clinic after 2002              NR                    NA                                                    NR
  Simek2012^31^                                  Retrospective cohort; 2002--2007, Czech Republic                               62 (34 vs 28)                                                                                         76% CABG, 6% valve, 18% CABG+valve                                                                                                      2002--2004: non-VAC2004--2007: VAC                                   KCI system            In-hospital                                               NR
  Steingrimsson2012^32^                              Retrospective cohort; 2000--2010, Iceland                                  43 (20 vs 23)                                                                              63% CABG, 16% AVR+CABG, 7% aortic valve replacement alone                                                                                          2000--2005: non-VAC2005--2010: VAC                                   KCI system            In-hospital                           Landspitali University Research Foundation
  Vos2012^33^                                      Retrospective cohort; 2000--2011, Netherlands                                132 (89 vs 43)                                                                                   81% CABG, 75% LIMA, 21% RIMA, 22% AVR, 8% MVR                                                                                             VAC or non-VAC; no reasons are reported                                     NR                In-hospital                                               NR
  Assmann2011^14^                                    Retrospective cohort; 2004--2008, Germany                                  154 (82 vs 72)                                                                                                     68% CABG                                                                                                                VAC or non-VAC; no reasons are reported                                 KCI system            In-hospital                                               NR
  De Feo2011^18^                                      Retrospective cohort; 1979--2009, Italy                                  200 (55 vs 145)                                                                        57% coronary artery bypass, 26% valve surgery, 18% other procedures                                                                                     1979--2002: non-VAC2002--2009: VAC                                   KCI system            In-hospital                                           Non-funded
  Kobayashi2011^25^                                   Retrospective cohort; 2001--2007, Japan                                    16 (9 vs 7)                                                                           44% CABG, 19% AVR, 31% thoracic aortic surgery, 6% cardiac trauma                                                                                      2001--2003: non-VAC2003--2007: VAC                                       NR               Undetermined                                               NR
  Morisaki2011^26^                                    Retrospective cohort; 1991--2010, Japan                                    59 (8 vs 51)                      58% CABG, 20% single-valve surgery, 8% OPCAB, 5% modified Bentall procedure, 5% thoracic aneurysm operation, 5% combined operations, 5% other, 2% CABG+infarct exclusion                                   1991--2006: non-VAC2006--2010: VAC                                       NR                In-hospital                                               NR
  Baillot2010^15^                    Retrospective cohort; 2002--2007[\*](#nt101){ref-type="table-fn"}, Canada                 149 (125 vs 24)                                                                                                     \(B\) IMA                                                                                                               VAC or non-VAC; no reasons are reported                                     NR                In-hospital                                               NR
  De Feo2010^17^                                      Retrospective cohort; 2000--2009, Italy                                   75 (45 vs 30)                                                                                                   Cardiac surgery                                                                                                            VAC or non-VAC; no reasons are reported                                 KCI system                NA                                                    NR
  Petzina2010^27^                                    Retrospective cohort; 2004--2009, Germany                                  118 (69 vs 49)                                                                                            84% CABG ± valve procedure                                                                                                          2004--2006: non-VAC2006--2009: VAC                                       NR                In-hospital                                               NR
  Eyileten2009^21^                                   Retrospective cohort; 2000--2007, Turkey                                   65 (33 vs 32)                                                                      75% CABG, 9% MVR, 5% MVR+CABG, 5% AVR, 2% AVR+CABG, 2% Bentall procedure                                                                                   2000--2004: non-VAC2005--2007: VAC                                   KCI system            In-hospital                                               NR
  Fuchs2005^23^                                      Retrospective cohort; 1998--2003, Germany                                  68 (35 vs 33)                                                                                     Bypass operations, heart valve replacements                                                                                                 1998--2000: non-VAC2000--2003: VAC                                   KCI system           Undetermined                                               NR
  Immer2005^24^                                    Retrospective cohort; 1998--2003, Switzerland                                55 (38 vs 17)                                                              76% CABG, 58% unilateral mammarian artery, 15% bilateral mammarian artery, 1% reoperation                                                       VAC or non-VAC;[§](#nt102){ref-type="table-fn"} no reasons are reported                 KCI system           Undetermined                                               NR
  Segers2005^30^                                   Retrospective cohort; 1992--2003, Netherlands                                63 (29 vs 34)                                                                            64% CABG, 14% valve surgery, 21% CABG+valve surgery, 2% other                                                                                     VAC or non-VAC; no reasons are reported                                 KCI system              30-day                                                  NR
  Sjögren2005^11^                                    Retrospective cohort; 1994--2003, Sweden                                   101 (61 vs 40)                                                                                          72% CABG, 28% other procedures                                                                                                        1994--1998: non-VAC1999--2003: VAC                                       NR                  90-day           County of Skåne Medical Science Fund, University Hospital of Lund Donation Funds
  Domkowski2003^20^                              Retrospective cohort; 1997--2002, United Kingdom                               102 (96 vs 6)                                                                                                   Cardiac surgery                                                                                                            VAC or non-VAC; no reasons are reported                                     NR                In-hospital                                               NR
  Doss2002^8^                                        Retrospective cohort; 1998--2000, Germany                                  42 (20 vs 22)                   69% CABG, 14% CABG+AVR, 5% CABG+carotid endarterectomy, 5% CABG +concomitant left ventricular aneurysm resection, 5% isolated AVR, 2% CABG+ concomitant AVR+mitral valve repair   1998--1999: non-VAC1999--2000: both non-VAC and VAC, according to the surgeon's discretion       KCI system            In-hospital                                               NR
  Berg2000^16^                                     Retrospective cohort; 1989--1997, Netherlands                                60 (31 vs 29)                                                           35% CABG with venous graft, 58% CABG with IMA, 5% valve replacement, 2% CABG+valve replacement                                                              VAC or non-VAC; according to the surgeon's discretion                              NR                In-hospital                                               NR

For patients treated for sternal wound infections between 1997 and 2001, no mortality data was available and therefore, they were not included in the analysis.

In this study, in a few patients, despite the availability of the VAC, a non-VAC therapy has been chosen due to the poor quality of the sternum (fractured, white aspect, fragile) or on the clinical situation with incontrollable infection and hemodynamic instability.

Mortality {#s3a}
---------

Twenty studies (2233 patients) provided data on mortality.[@pone.0064741-Doss1], [@pone.0064741-Sjogren1], [@pone.0064741-Assmann1], [@pone.0064741-Baillot1], [@pone.0064741-Berg1], [@pone.0064741-DeFeo2], [@pone.0064741-Deniz1], [@pone.0064741-Domkowski1], [@pone.0064741-Eyileten1], [@pone.0064741-Fleck2], [@pone.0064741-Fuchs1], [@pone.0064741-Immer1], [@pone.0064741-Kobayashi1], [@pone.0064741-Morisaki1], [@pone.0064741-Petzina1], [@pone.0064741-Risnes1], [@pone.0064741-Segers1], [@pone.0064741-Simek1], [@pone.0064741-Steingrimsson1], [@pone.0064741-Vos1] ^refs^ Nineteen studies reported on deep sternal wound infections (15 on mediastinitis,[@pone.0064741-Sjogren1], [@pone.0064741-Assmann1], [@pone.0064741-Baillot1], [@pone.0064741-Berg1], [@pone.0064741-DeFeo2], [@pone.0064741-Deniz1], [@pone.0064741-Domkowski1], [@pone.0064741-Eyileten1], [@pone.0064741-Fuchs1], [@pone.0064741-Kobayashi1], [@pone.0064741-Morisaki1], [@pone.0064741-Petzina1], [@pone.0064741-Risnes1], [@pone.0064741-Segers1], [@pone.0064741-Steingrimsson1], [@pone.0064741-Vos1] 2 on osteomyelitis[@pone.0064741-Doss1], [@pone.0064741-Kobayashi1] and 2 did not specify the type of infections[@pone.0064741-Immer1], [@pone.0064741-Simek1]). One study included both deep (69%) and superficial (31%) sternal wound infections.[@pone.0064741-Fleck2] In 12 studies, VAC treated patients were compared with a historical control group not receiving VAC therapy,[@pone.0064741-Sjogren1], [@pone.0064741-DeFeo2], [@pone.0064741-Deniz1], [@pone.0064741-Eyileten1], [@pone.0064741-Fleck2], [@pone.0064741-Fuchs1], [@pone.0064741-Kobayashi1], [@pone.0064741-Morisaki1], [@pone.0064741-Petzina1], [@pone.0064741-Risnes1], [@pone.0064741-Simek1], [@pone.0064741-Steingrimsson1] while in 2 other studies,[@pone.0064741-Doss1], [@pone.0064741-Berg1] the selection of therapy (VAC or non-VAC) was at the surgeon's discretion, as both types of therapy were simultaneously available. Six studies did not provide the criteria for the selection of therapy in the enrolled patients.[@pone.0064741-Assmann1], [@pone.0064741-Baillot1], [@pone.0064741-Domkowski1], [@pone.0064741-Immer1], [@pone.0064741-Segers1], [@pone.0064741-Vos1] Twelve studies provided data for in-hospital mortality,[@pone.0064741-Doss1], [@pone.0064741-Assmann1], [@pone.0064741-Baillot1], [@pone.0064741-Berg1], [@pone.0064741-DeFeo2], [@pone.0064741-Domkowski1], [@pone.0064741-Eyileten1], [@pone.0064741-Morisaki1], [@pone.0064741-Petzina1], [@pone.0064741-Simek1], [@pone.0064741-Steingrimsson1], [@pone.0064741-Vos1] 2 on 30-day[@pone.0064741-Risnes1], [@pone.0064741-Segers1] and 2 studies on 90-day mortality,[@pone.0064741-Sjogren1], [@pone.0064741-Deniz1] while 4 studies did not determine when mortality was assessed.[@pone.0064741-Fleck2], [@pone.0064741-Fuchs1], [@pone.0064741-Immer1], [@pone.0064741-Kobayashi1].

Pooling of all 20 studies that provided data on mortality showed that patients treated with VAC had significantly lower mortality compared to those treated with a non-VAC therapy, \[[Figure 2](#pone-0064741-g002){ref-type="fig"}, 2233 patients, RR = 0.40, (95% CI: 0.28, 0.57)\]. Heterogeneity was not observed in this analysis (*I* ^2^ = 16%). In addition, mortality was lower among patients receiving VAC therapy after the exclusion of studies that showed significantly lower mortality \[1058 patients, RR 0.60, (95% CI: 0.41--0.89)\]. Lower mortality was found among patients treated with VAC among studies using a historical non-VAC control group \[1476 patients, RR = 0.32 (95% CI: 0.20, 0.50)\]. Heterogeneity was not observed in this analysis (*I* ^2^ = 5%). Similarly, lower mortality was observed for VAC therapy in the studies that did not provide the criteria for the selection of therapy \[655 patients, RR = 0.45 (95% CI: 0.23, 0.88)\]. No difference was found between the compared groups when the selection of the type of therapy was at the surgeon's discretion \[102 patients, RR = 0.99, (95% CI: 0.21, 4.65)\].

![Forest plot depicting the risk ratios (RR) of mortality of patients according to the selection of the type of therapy.\
(*Vertical line = \"no difference\" point between the two regimens. Squares = risk ratios; Diamonds = pooled risk ratios for all studies. Horizontal lines = 95% CI*).](pone.0064741.g002){#pone-0064741-g002}

In-hospital mortality was lower among patients treated with a VAC compared to those treated with a non-VAC therapy, \[[Figure 3](#pone-0064741-g003){ref-type="fig"}, 1186 patients, RR = 0.40, (95% CI: 0.26, 0.62)\]. Heterogeneity was not observed in this analysis (*I* ^2^ = 13%). On the other hand, no difference in 30-day \[193 patients, RR = 2.28 (95% CI: 0.30, 17.25)\] and 90-day mortality \[191 patients, RR = 0.21 (95% CI: 0.03, 1.30)\]; a small number of patients were included in these 2 analyses. Finally, in the studies that did not provide the time of mortality assessment a trend towards lower mortality was observed \[663 patients, RR = 0.39 (95% CI: 0.14, 1.03)\].

![Forest plot depicting the risk ratios (RR) of mortality of patients according to the time of mortality assessment.\
(*Vertical line = \"no difference\" point between the two regimens. Squares = risk ratios; Diamonds = pooled risk ratios for all studies. Horizontal lines = 95% CI*).](pone.0064741.g003){#pone-0064741-g003}

Patients with mediastinitis and/or undetermined deep sternal wound infections treated with VAC therapy had lower mortality compared to the respective patients treated with a non-VAC therapy, \[[Figure 4](#pone-0064741-g004){ref-type="fig"}, 1534 patients, RR = 0.38 (95% CI: 0.24, 0.60)\] and \[117 patients, RR = 0.21 (95% CI: 0.06, 0.73)\] respectively. Heterogeneity was not observed in the abovementioned analyses (*I* ^2^ = 23% and *I* ^2^ = 0%, respectively). No difference in mortality was found between the compared groups among patients with osteomyelitis \[58 patients, RR = 1.78 (95% CI: 0.35, 9.04)\]. Last, 1 study including both deep and superficial sternal wound infections showed lower mortality among patients treated with VAC therapy than those treated with a non-VAC therapy \[524 patients, RR = 0.36 (95% CI: 0.18, 0.73)\].[@pone.0064741-Fleck2].

![Forest plot depicting the risk ratios (RR) of mortality of patients according to the type of infection studied.\
(*Vertical line = \"no difference\" point between the two regimens. Squares = risk ratios; Diamonds = pooled risk ratios for all studies. Horizontal lines = 95% CI*).](pone.0064741.g004){#pone-0064741-g004}

Only 4 of the 20 studies provided data regarding funding; 1 was industry-funded,[@pone.0064741-Fleck2] 2 were funded by universities[@pone.0064741-Sjogren1], [@pone.0064741-Steingrimsson1] while 1 study was not funded.[@pone.0064741-DeFeo2] Therefore, potential bias arising out of funding could not be adequately investigated.

Recurrences, Complications and Length of Stay {#s3b}
---------------------------------------------

Ten studies provided data on recurrence of DSWIs (1197 patients).[@pone.0064741-Sjogren1], [@pone.0064741-DeFeo1], [@pone.0064741-Eyileten1], [@pone.0064741-Fleck2], [@pone.0064741-Kobayashi1], [@pone.0064741-Petzina1], [@pone.0064741-Risnes1], [@pone.0064741-Segers1], [@pone.0064741-Simek1], [@pone.0064741-Steingrimsson1] Pooling of these studies showed that recurrence was less common among patients treated with VAC compared to those treated with a non-VAC therapy, \[RR = 0.34 (95% CI: 0.19, 0.59)\]. Moderate heterogeneity was detected in this analysis (*I* ^2^ = 48%). Data on complications was available within 4 studies.[@pone.0064741-Sjogren1], [@pone.0064741-Assmann1], [@pone.0064741-Eyileten1], [@pone.0064741-Simek1] Different types of complications were reported in the individual studies including remote infections, sepsis, cardiovascular/neurological/gastrointestinal complications, renal failure, bleeding, multiple organ failure, fistula, empyema, dehiscence, skin graft requirement, skin necrosis, seroma, discharging sinus, partial flap loss, new atrial fibrillation. However, only one study presented the total number of complications patients in each treatment arm,[@pone.0064741-Assmann1] while the remaining three studies presented the individual complications in each arm.[@pone.0064741-Sjogren1], [@pone.0064741-Eyileten1], [@pone.0064741-Simek1] Therefore, the data could not be further analyzed.

Finally, ten studies provided data on LOS (983 patients).[@pone.0064741-Doss1], [@pone.0064741-Sjogren1], [@pone.0064741-Assmann1], [@pone.0064741-Berg1], [@pone.0064741-Deniz1], [@pone.0064741-Eyileten1], [@pone.0064741-Petzina1], [@pone.0064741-RodriguezCetinaBiefer1], [@pone.0064741-Simek1], [@pone.0064741-Vos1] Pooling of the outcomes of these studies showed that there was no statistically significant difference in LOS between patients treated with VAC and those treated with a non-VAC therapy, \[RR = −2.25 (95% CI: −7.52, 3.02)\]. Considerable heterogeneity was detected in this analysis (*I* ^2^ = 82%) and individual studies showed that VAC was associated with both significantly lower and higher duration of hospitalization.

Discussion {#s4}
==========

The currently available data from retrospective cohort studies suggest that the use of VAC therapy was associated with lower mortality than non-VAC therapy for the treatment of patients with DSWIs after cardiovascular surgery. This finding was consistently present regardless the study design, the inclusion of studies with positive findings, the criteria for establishment of the compared groups, the time of mortality assessment or the type of infections under study, provided that adequate data was available. In addition, VAC therapy was associated with fewer recurrences of infections. On the contrary, this meta-analysis did not show any difference in the duration of hospitalization.

The main limitation of the current meta-analysis is the retrospective nature of the available data. No randomized controlled trial has been published yet and one protocol had been registered --to our knowledge? regarding the effectiveness and safety of VAC therapy for the treatment of patients with DSWIs in which mortality is the primary end-point.[@pone.0064741-Sood1] In addition, only one of the included studies performed a multivariate analysis to identify independent predictors for survival; VAC therapy was not introduced into this model and methicillin-resistant *Staphylococcus aureus* was the sole independent predictor for mortality.[@pone.0064741-Morisaki1] Therefore, only unadjusted data were available for comparisons. A variety of techniques were used for the management of DSWIs in the control groups of both the individual studies and between studies; in addition, VAC was not the sole intervention applied in the VAC group of patients in all studies. As this clinical heterogeneity was expected, a random effect model was selected for all comparisons prior to the implementation of the meta-analysis. On the other hand, statistical heterogeneity was not observed in any of the performed analyses and all subgroup analyses consistently confirmed the results of the primary analysis, thus strengthening the validity of the results of the meta-analysis. Data regarding the offending bacteria and corresponding antibiotic treatment was not available. Finally, outcomes regarding the way of using VAC (i.e. pressure or duration) were not available within the included studies.

A recent international consensus conference suggested certain non-surgical interventions that are documented as decreasing mortality after a cardiac surgery and need further study;[@pone.0064741-Landoni1] administration of insulin, levosimendan, volatile anesthetics, statins, chronic beta-blockade, early aspirin therapy, the use of preoperative intra-aortic balloon counterpulsation are encountered among them. VAC therapy could be also included in this list if the lower mortality finding is confirmed in randomized studies. VAC therapy is not approved officially for the treatment of DSWIs. However, the positive findings of early studies showing lower mortality (although not uniformly) or decreased duration of hospitalization,[@pone.0064741-Doss1], [@pone.0064741-Sjogren1], [@pone.0064741-Sjogren2], [@pone.0064741-Berg1] in addition to better outcomes in favor of VAC therapy from RCTs in other patient populations, prompted the experts in the field to recommend the wider use of VAC for the treatment of patients with DSWIs.[@pone.0064741-Bovill1], [@pone.0064741-Fleck1] It should be noted that VAC is recommended "before primary closure, as preparation for secondary closure with vascularised tissue and as an adjunct to flap healing".[@pone.0064741-Bovill1], [@pone.0064741-Fleck1].

Few studies provided data regarding recurrent DSWIs and even fewer for systemic or related to the surgical interventions complications. VAC therapy was associated with fewer recurrences than conventional treatment in the meta-analysis. Data regarding complications could not be further analyzed and adverse events following VAC and non-VAC therapy were not studied in this meta-analysis. In face of potentially lower mortality, the development of complications and adverse events seems negligible. However, surgeons should be aware of them in order to improve the quality of life of their patients. Complications of VAC treatment include bleeding (although sometimes its presence can be attributed to factors other than the VAC itself),[@pone.0064741-vanWingerden1] decrease of cardiac output when it is applied directly on the heart,[@pone.0064741-Conquest1] and adhesion formation and organ injury after the application of vacuum.[@pone.0064741-Fleck1] Advisory panels also warn against the use of VAC therapy when the patient has excessive or uncontrolled bleeding or uses anticoagulants that results in international normalized ratio over 2, untreated or undebrided osteomyelitis, and chest or pulmonary malignancy.[@pone.0064741-Fleck1].

Infections are among the major complications that prolong hospitalization. Controversial results were reported regarding this outcome in the studies included in the meta-analysis; six studies reported that LOS was significantly lower in patients receiving VAC therapy, while two reported that LOS was significantly prolonged. The meta-analysis including 10 studies showed no difference in the LOS when VAC was used, but considerable statistical heterogeneity was found. Therefore, it is difficult to draw conclusions regarding LOS. A recently published meta-analysis concluded that LOS was shortened with the use of VAC.[@pone.0064741-Damiani1] This meta-analysis included data from 6 studies; 3 of them were also included in the present meta-analysis. One did not provide the mean and standard deviation,[@pone.0064741-Catarino1] one provided the mean but not the standard deviation,[@pone.0064741-Segers1] and one provided separate data for two groups of patients receiving VAC;[@pone.0064741-Immer1] since we did not contact with the corresponding authors to request additional data, these data could not be included in the meta-analysis. Since hospital cost is associated mainly with LOS, these findings question the cost-effectiveness of VAC therapy in this patient population. Different findings in favor or against VAC regarding cost-effectiveness have been published.[@pone.0064741-Braakenburg1], [@pone.0064741-Mokhtari1], [@pone.0064741-Othman1], [@pone.0064741-Soares1].

In conclusion, the currently available data suggest a lower mortality and support the use of VAC therapy for the treatment of patients with DSWIs following cardiothoracic surgery. The retrospective design of the studies included in the meta-analysis and the lack of adjusted data highlighting VAC as an independent predictor of survival suggest that a well designed RCT is warranted to study the effects of VAC therapy, alone or in combination with other techniques, on mortality of patients with DSWIs. The effect of VAC on LOS and the related cost should be further investigated in this patient population.
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